Drug Trial Radar · NCT02988973
A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
334
Actual
Start
Jan 12, 2017
Primary completion
Sep 13, 2019
Study completion Mar 26, 2020
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Kyntra Bio
- First posted
- Dec 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).
Conditions
- Chronic Kidney Disease
Interventions
roxadustatDrug
Oral administration
DADrug
Subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the average Hemoglobin (Hb)Time frame: Baseline and Weeks 18 to 24
Locations
66 sites in 1 country. Site status is shown where the registry gives one.
Site JP00014
Fukui, Japan
Site JP00033
Fukuoka, Japan
Site JP00065
Fukuoka, Japan
Site JP00032
Hiroshima, Japan
Site JP00039
Hiroshima, Japan
Site JP00045
Kyoto, Japan
Site JP00018
Nagano, Japan
Site JP00068
Nagano, Japan
Site JP00026
Niigata, Japan
Site JP00034
Ōita, Japan
Site JP00055
Okayama, Japan
Site JP00056
Osaka, Japan
Site JP00061
Osaka, Japan
Site JP00010
Toyama, Japan
Site JP00009
Kasugai, Aichi-ken, Japan
Site JP00030
Nagoya, Aichi-ken, Japan
Site JP00051
Nagoya, Aichi-ken, Japan
Site JP00021
Toyohashi, Aichi-ken, Japan
Site JP00003
Sakura, Chiba, Japan
Site JP00038
Matsuyama, Ehime, Japan
Site JP00044
Matsuyama, Ehime, Japan
Site JP00008
Kitakyushu, Fukuoka, Japan
Site JP00013
Kitakyushu, Fukuoka, Japan
Site JP00040
Kitakyushu, Fukuoka, Japan
Site JP00057
Kitakyushu, Fukuoka, Japan
Site JP00042
Kurume, Fukuoka, Japan
Site JP00041
Tajimi, Gifu, Japan
Site JP00002
Maebashi, Gunma, Japan
Site JP00037
Hatsukaichi, Hiroshima, Japan
Site JP00050
Kure, Hiroshima, Japan
Site JP00049
Aasahikawa, Hokkaido, Japan
Site JP00007
Sapporo, Hokkaido, Japan
Site JP00064
Sapporo, Hokkaido, Japan
Site JP00022
Amagasaki, Hyōgo, Japan
Site JP00066
Nishinomiya, Hyōgo, Japan
Site JP00052
Hitachi, Ibaraki, Japan
Site JP00017
Kasama, Ibaraki, Japan
Site JP00028
Koga, Ibaraki, Japan
Site JP00053
Naka, Ibaraki, Japan
Site JP00023
Sashima-gun, Ibaraki, Japan
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.